Skip to main content
Fig. 1 | Journal of Ovarian Research

Fig. 1

From: Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis

Fig. 1

C-Myb and cisplatin resistance. C-Myb levels were detected in parental and cisplatin resistant ES2 (A) and A2780 (B) cells. Cell proliferation, to assess cytotoxic effects of increasing cisplatin, was assessed in parental and cisplatin resistant ES2 (C) and A2780 (D) cells with an additional silencing of c-Myb in resistant cells (ES2C-si / A2780C-si). The presented results are representative of at least 3 different repeats with triplicate samples in each repeat. #p<0.05, compared to control. *p<0.05, compared to resistant cells without silencing of c-Myb.

Back to article page